A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China

Abstract Background High-risk neuroblastoma (HR-NB) is associated with high metastatic and relapse rates that require intensive multimodal treatment. We evaluated the efficacy and safety of dinutuximab beta as first-line maintenance immunotherapy in pediatric patients with HR-NB in real-world clinic...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Xuedi Yu, Suyi Kang, Junjie Ge, Jingfu Wang
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2025-03-01
Sarja:	BMC Pediatrics
Aiheet:	High-risk neuroblastoma Dinutuximab beta GD2-antibody immunotherapy GM-CSF First-line maintenance Chemotherapy
Linkit:	https://doi.org/10.1186/s12887-025-05568-x
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!